Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.On the 13th, the No.20 rubber fell by 2.05%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract No.20 rubber 2502 was closed, with a turnover of 159,100 lots. The position data showed that the top 20 seats were clear, and the difference position was 5,142 lots. A total of 205,200 lots were traded in the No.20 rubber futures contract, an increase of 8,176 lots over the previous day. The first 20 seats in the contract held 84,200 lots, an increase of 812 lots over the previous day. Short positions in the top 20 seats of the contract were 94,500 lots, a decrease of 1,708 lots from the previous day. (Sina Futures)On the 13th, SSE 50 index futures fell by 2.58%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, SSE 50 index futures closed at 2,412, up or down by -2.58%, with a turnover of 53,000 lots. The position data showed that the top 20 seats were clear, and the difference position was 7,398 lots. The total number of contracts of SSE 50 index futures was 91,500 lots, an increase of 25,700 lots over the previous day. The first 20 seats in the contract held 88,200 lots, an increase of 2,257 lots over the previous day. The short positions in the top 20 seats of the contract were 113,700 lots, an increase of 1,701 lots over the previous day. (Sina Futures)
Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.The White House commuted the sentences of 1,500 people in one day, and Biden pardoned 39 people in one day. According to Agence France-Presse reported on December 12, US President Biden commuted the sentences of nearly 1,500 people and pardoned 39 people at the end of his term. The White House said that this was the "largest" leniency action in a single day in American history. Biden announced on the 12th that about 1,500 people would be commuted, and at the same time, 39 non-violent offenders would be pardoned, saying that they had turned over a new leaf and were committed to making the community safer. (Reference message)
Asia-Pacific Pharmaceuticals: The new specifications of cefmetazole sodium for injection were approved, and Asia-Pacific Pharmaceuticals announced that the company was approved by National Medical Products Administration, and the new specifications of cefmetazole sodium for injection were 0.5g and 2g, which further enriched the product categories on the basis of the original 1g specifications. The annual sales income of this drug in 2023 was 96.3946 million yuan, accounting for 22.92% of the company's operating income. New specifications are helpful to market promotion and competitiveness improvement, but drug production and sales are affected by policies and market environment, and there are uncertainties.The new CEO of Pakistan Stock Exchange said that the exchange is seeking to provide traders with the option of cash settlement of futures trading, and plans to conduct a test before March next year.Shanghai Gold Exchange: the settlement price of NYAuTN12 contract in Shanghai New Zealand was 627.85 yuan/gram. On December 13th, Shanghai Gold Exchange issued a notice saying that NYAuTN12 contract in Shanghai New Zealand was settled on December 13th, 2024. The details of the settlement of the contract are as follows: the settlement price of NYAuTN12 contract in Shanghai New Zealand was 627.85 yuan/gram.
Strategy guide
12-14
Strategy guide 12-14
Strategy guide
12-14